Loading clinical trials...
Loading clinical trials...
Frequency of Abnormal Glucose Metabolism (Diabetes, Impaired Glucose Tolerance, Impaired Fasting Glucose) in the Immediate Postpartum Period Following Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation
The main objective of the study is to estimate and compare the percentage of patients with abnormal glucose metabolism at 4-12 weeks postpartum between two groups: patients diagnosed with gestational diabetes before or after 24 weeks of pregnancy. Abnormal glucose metabolism is defined as type 2 diabetes, glucose intolerance or impaired fasting glucose.
The secondary objectives of this study are to compare between the two groups: A. the rate of type 2 diabetes only, glucose intolerance only, impaired fasting glucose only, and patients requiring insulin at 4-12 weeks postpartum B. rates of maternal and obstetric complications C. risk factors (age, body mass index, personal history of gestational diabetes or macrosomia, first degree family history of diabetes). D. For fasting glucose done before 24SA, we will calculate the optimal threshold for predicting abnormal glucose metabolism in the immediate postpartum period among women with gestational diabetes.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
CH d'Arles - Hôpital Joseph Imbert
Arles, France
CHU de Montpellier - Hôpital Arnaud de Villeneuve
Montpellier, France
CHU de Montpellier - Hôpital Lapeyronie
Montpellier, France
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, France
Start Date
March 27, 2014
Primary Completion Date
October 12, 2016
Completion Date
October 12, 2016
Last Updated
November 19, 2025
500
ACTUAL participants
Post-partum oral glucose tolerance test
BIOLOGICAL
Lead Sponsor
Centre Hospitalier Universitaire de Nīmes
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06671587